Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 13/20 | 0.38 |
| ▸ | GRIA1 | P42261 | 4/20 | 0.36 |
| ▸ | GRIA2 | P42262 | 4/20 | 0.36 |
| ▸ | GRIA3 | P42263 | 4/20 | 0.36 |
| ▸ | GRIA4 | P48058 | 4/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.34 |
| ▸ | ADRA1B | P35368 | 4/20 | 0.34 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.33 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20992167 | 0.87 | ADRA1D (0.46) | ADRA1DGRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL17033306 | 0.80 | CA1 (0.45) | ADRA1DGRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL17050353 | 0.80 | CA2 (0.40) | ADRA1DGRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL2355589 | 0.79 | ADRA1D (0.40) | ADRA1DGRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL17031835 | 0.78 | ADRA1D (0.39) | ADRA1DGRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL20992182 | 0.76 | CHRNA1 (0.36) | GRIA2ABCC8KCNJ11 | |
| SCHEMBL20671092 | 0.72 | ADRA1D (0.41) | ADRA1DGRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL17050355 | 0.70 | ADRA1D (0.46) | ADRA1DCA1CA2ADRA1AADRA1B | |
| SCHEMBL17033295 | 0.70 | CA1 (0.56) | ADRA1DCA1CA2ADRA1AADRA1B | |
| SCHEMBL2355322 | 0.69 | ADRA1D (0.45) | ADRA1DGRIA1GRIA2GRIA3GRIA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4129407-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Achillion Pharmaceuticals, Inc. (US) | 2023-02-08 | — | — | EP | disclosed |
| EP-3110418-B1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS INC (US) | 2019-11-06 | — | — | EP | disclosed |
| US-10287301-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10287301-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | CFD, F12, F3 | ADRA1D 199/4885GRIA1 3542/4885GRIA2 3130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.